These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 2294381)
21. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]
22. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned. Mathis LL; Iyasu S Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537 [TBL] [Abstract][Full Text] [Related]
23. The impact of FDA reform. Trunzo J Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699 [TBL] [Abstract][Full Text] [Related]
25. [Nutriceuticals]. Martin A Rev Prat; 1999 Oct; 49(16):1721-2. PubMed ID: 10578600 [No Abstract] [Full Text] [Related]
26. "Junk science" in the courtroom. Causes and effects. Price JM; Gates GS ASAIO J; 1995; 41(2):139-42. PubMed ID: 7640415 [No Abstract] [Full Text] [Related]
27. FDA cracks down on labeling, initiates trial result reporting. Osborne R; Waltz E Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742 [No Abstract] [Full Text] [Related]
28. Medicine. Ephedra--scientific evidence versus money/politics. Wolfe SM Science; 2003 Apr; 300(5618):437. PubMed ID: 12702860 [No Abstract] [Full Text] [Related]
29. Regulatory decisions and consumers. Rawlins MD Med Toxicol; 1986; 1 Suppl 1():128-9. PubMed ID: 3821428 [TBL] [Abstract][Full Text] [Related]
30. [Pharmacovigilance off the beaten track: herbal surveillance or pharmacovigilance of medicinal plants]. Castot A; Djezzar S; Deleau N; Guillot B; Efthymiou ML Therapie; 1997; 52(2):97-103. PubMed ID: 9231502 [TBL] [Abstract][Full Text] [Related]
31. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration? Zelenay JL Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773 [No Abstract] [Full Text] [Related]
35. International reporting on adverse drug reactions: the CIOMS project. CIOMS ADR Working Group. Faich GA; Castle W; Bankowski Z Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):133-8. PubMed ID: 2338366 [TBL] [Abstract][Full Text] [Related]
36. Post marketing surveillance of new drugs. Patient safety in the hands of GPs. Marley JE Aust Fam Physician; 1989 Sep; 18(9):1133-5. PubMed ID: 2590077 [TBL] [Abstract][Full Text] [Related]
38. Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. Harrison-Woolrych M; Hill R Contraception; 2005 Apr; 71(4):306-8. PubMed ID: 15792651 [TBL] [Abstract][Full Text] [Related]
39. [Pharmacovigilance: a case of phantom ships and Russian roulette]. Stricker BH Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668 [TBL] [Abstract][Full Text] [Related]
40. Cyclooxygenase-2 inhibitors and cardiovascular risk. Smith ER Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]